370 related articles for article (PubMed ID: 8527411)
1. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
Zou JP; Yamamoto N; Fujii T; Takenaka H; Kobayashi M; Herrmann SH; Wolf SF; Fujiwara H; Hamaoka T
Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
[TBL] [Abstract][Full Text] [Related]
2. Antitumor and antimetastatic effects of interleukin 12.
Fujiwara H; Hamaoka T
Cancer Chemother Pharmacol; 1996; 38 Suppl():S22-6. PubMed ID: 8765411
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
Li XF; Takiuchi H; Zou JP; Katagiri T; Yamamoto N; Nagata T; Ono S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1993 Mar; 84(3):315-25. PubMed ID: 8098027
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor effects of IL-12 involve enhanced IFN-gamma production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-gamma production.
Fujiwara H; Hamaoka T
Leukemia; 1997 Apr; 11 Suppl 3():570-1. PubMed ID: 9209457
[TBL] [Abstract][Full Text] [Related]
5. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
[TBL] [Abstract][Full Text] [Related]
6. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways.
Yu WG; Ogawa M; Mu J; Umehara K; Tsujimura T; Fujiwara H; Hamaoka T
J Leukoc Biol; 1997 Oct; 62(4):450-7. PubMed ID: 9335314
[TBL] [Abstract][Full Text] [Related]
7. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12.
Yu WG; Yamamoto N; Takenaka H; Mu J; Tai XG; Zou JP; Ogawa M; Tsutsui T; Wijesuriya R; Yoshida R; Herrmann S; Fujiwara H; Hamaoka T
Int Immunol; 1996 Jun; 8(6):855-65. PubMed ID: 8671675
[TBL] [Abstract][Full Text] [Related]
9. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.
Yamamoto N; Zou JP; Li XF; Takenaka H; Noda S; Fujii T; Ono S; Kobayashi Y; Mukaida N; Matsushima K
J Immunol; 1995 Mar; 154(5):2281-90. PubMed ID: 7868900
[TBL] [Abstract][Full Text] [Related]
10. B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state.
Wijesuriya R; Maruo S; Zou JP; Ogawa M; Umehara K; Yamashita M; Ono S; Fujiwara H; Hamaoka T
Int Immunol; 1998 Aug; 10(8):1057-65. PubMed ID: 9723691
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo recovery of IFN-gamma, but not IL-2, production by IL-12 in mice with plasma cell tumors.
Ruzek MC; Mathur A
Int Immunol; 1996 Mar; 8(3):413-22. PubMed ID: 8671628
[TBL] [Abstract][Full Text] [Related]
12. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.
Ahn HJ; Maruo S; Tomura M; Mu J; Hamaoka T; Nakanishi K; Clark S; Kurimoto M; Okamura H; Fujiwara H
J Immunol; 1997 Sep; 159(5):2125-31. PubMed ID: 9278298
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.
Taniguchi F; Yamagishi H; Fujiwara H; Ueda Y; Fuji N; Yoshimura T; Oka T
Gene Ther; 1998 Dec; 5(12):1677-84. PubMed ID: 10023447
[TBL] [Abstract][Full Text] [Related]
14. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
15. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models.
Iwasaki M; Yu WG; Uekusa Y; Nakajima C; Yang YF; Gao P; Wijesuriya R; Fujiwara H; Hamaoka T
Int Immunol; 2000 May; 12(5):701-9. PubMed ID: 10784616
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
17. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells.
Bohn E; Autenrieth IB
J Immunol; 1996 Feb; 156(4):1458-68. PubMed ID: 8568248
[TBL] [Abstract][Full Text] [Related]
18. Exogenous interleukin-3 enhances IL-4 production by splenic CD4+ cells during the early stages of a Trichinella spiralis infection.
Korenaga M; Akimaru Y; Hashiguchi Y
Int Arch Allergy Immunol; 1998 Oct; 117(2):131-7. PubMed ID: 9784657
[TBL] [Abstract][Full Text] [Related]
19. IL-28 elicits antitumor responses against murine fibrosarcoma.
Numasaki M; Tagawa M; Iwata F; Suzuki T; Nakamura A; Okada M; Iwakura Y; Aiba S; Yamaya M
J Immunol; 2007 Apr; 178(8):5086-98. PubMed ID: 17404291
[TBL] [Abstract][Full Text] [Related]
20. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis.
Mizuhara H; Uno M; Seki N; Yamashita M; Yamaoka M; Ogawa T; Kaneda K; Fujii T; Senoh H; Fujiwara H
Hepatology; 1996 Jun; 23(6):1608-15. PubMed ID: 8675184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
